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Background: Placebo-controlled surgical trials can provide important information about the efficacy of surgical
interventions. However, they are ethically contentious as placebo surgery entails the risk of harms to recipients,
such as pain, scarring or anaesthetic misadventure. This has led to claims that placebo-controlled surgical trials
are inherently unethical. On the other hand, without placebo-controlled surgical trials, it may be impossible to
know whether an apparent benefit from surgery is due to the intervention itself or to the placebo effect.
Discussion: In this paper we investigate justifications for placebo-controlled surgical trials and suggest three
measures for strengthening their ethical acceptability. We argue that, given the extent, irreversibility and cost
of surgical interventions, there is a need for the best possible evidence about their efficacy. In some cases, the
strongest evidence will be from placebo-controlled surgical trials, especially where interventions are for outcomes
(such as pain) that are likely to elicit a placebo response. In the second part of the paper, we propose three
specific measures to increase the ethical acceptability of placebo-controlled surgical trials. The first is structured
consultation with the relevant patient community about the risks and benefits of particular placebo-controlled
surgical trials. The second seeks to address the therapeutic misconception through the use of educational
materials, informed by patient consultation. Finally, we argue for ethical consideration of non-surgeon clinicians
who are necessarily involved in the delivery of placebo-surgical interventions.
Summary: If there is no appropriate surgical comparator and the risks can be reduced to the absolute minimum
(given the type of placebo procedure required), and the research has the support of the relevant patient community,
there may be grounds for judging that the potential benefits of specific placebo-controlled surgical trials outweigh
the risks. If so justified, the ethical acceptability of placebo-controlled surgical trials can be enhanced through
using educational measures to address participant vulnerability, and by recognizing clinicians who are necessary
participants in the research.
Keywords: Placebo-controlled surgical trials, Research ethics, Therapeutic misconception, Research methods,
Surgical research, Efficacy, Placebo effect, Consumer involvementBackground
With surgery, as with other branches of health care, it is
desirable to have evidence that the intervention in question
works (achieves the intended outcomes) before offering it
to patients. Otherwise, patients may be exposed to invasive
and harmful procedures for little or no benefit. Clinical
trials measure efficacy by testing the intervention against a
comparator of known efficacy, or where there is no suitable
comparator, against a placebo. The most rigorous clinical* Correspondence: wendy.rogers@mq.edu.au
1Department of Philosophy and Australian School of Advanced Medicine,
Macquarie University, Sydney, NSW, 2109, Australia
Full list of author information is available at the end of the article
© 2014 Rogers et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.trials blind both clinicians and participants as to who is
receiving the intervention in question; so that any effects
may be attributed to the intervention itself. In surgical
research where there is no suitable comparator, proving
efficacy may require the use of placebos. This entails
exposing participants to a placebo or sham operation,
with potential risk of harms. Placebos are procedures
that are considered to be ‘inert’ [1]. In surgery, a placebo
mimics the surgical intervention but without the intended
therapeutic procedure. Surgical placebos vary in their
degree of invasiveness. Some may avoid general anaesthe-
sia and use incisions that penetrate the epidermis only [2]
while others involve anaesthesia, and create surgicalLtd. This is an Open Access article distributed under the terms of the Creative
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placebos need to be plausible, they raise serious questions
about the potential levels of harm to which trial partici-
pants may be exposed for the purposes of research.
The issue of knowingly exposing participants in placebo-
controlled surgical trials (PCSTs) to the harms of a
sham procedure has polarised debate about their ethical
acceptability [4-8]. The debate has been framed as a
clash between the highest standards of research design
and the highest standards of research ethics [8].
Proponents of PCSTs argue that these trials are some-
times necessary to find out whether particular surgical
interventions are efficacious, or whether any observed
changes in a patient’s condition are due to a placebo
effect [3,7,9,10].a The requirement to minimise the risk
of harms is understood to be ethically important, but
not one that necessarily overrides the requirement for
research to be of the highest scientific standards [7,11,12].
Taking this view, researchers are obliged to minimise
the risks consistent with using the most appropriate
trial design [13], which in surgery, may be a PCST in
order to answer questions about efficacy. Without such
answers, surgical patients, sometimes many thousands,
are potentially exposed to surgical interventions that may
be ineffective – described by one surgeon as no better
than “glorified acupuncture” [14]. A trial that identifies a
surgical intervention as no better than placebo has signifi-
cant implications for practice. For example, Sihvonen
et al. [15] estimate that upward of 700,000 patients in the
US undergo arthroscopic partial meniscectomies each
year, yet their trial shows the procedure to be no better
than placebo across a range of outcomes. Those support-
ive of PCSTs acknowledge that participants may be
harmed by receiving a sham procedure, but claim that the
risk of harm (in at least some trials) can be minimized to
the extent that it becomes reasonable to make a judgment
about the balance between these risks and the value to
society of the potential knowledge to be gained about the
intervention’s efficacy. On their account, ethical bodies
responsible for reviewing research (institutional review
boards – IRBs) should make this judgment and approve
methodologically rigorous PCSTs in which the risk of
harms have been minimised, leaving the ultimate decision
as to whether the risks of placebo trial participation are
worthwhile to prospective participants, duly protected by
adequate informed consent processes.
Conversely, opponents of PCSTs claim that placebo
surgery is inherently harmful and therefore breaches the
ethical obligations of researchers to minimise risk of
harm to participants [5,6,16]. On this view, any risk of
harm to individuals is unacceptable. Notwithstanding
that PCSTs will yield information about the efficacy of
surgical interventions that is otherwise unobtainable, for
Macklin, “performing a surgical procedure that has noexpected benefit other than the placebo effect violates
the ethical and regulatory principle that the risk of harm
to subjects must be minimized in the conduct of research”
[6], p. 993. Macklin and others [5,16] argue that the ethical
injunction to minimize the risk of harms must take
precedence over any likely gains to knowledge, no matter
how great their promise. These authors argue that informed
consent is inadequate to protect participants. In their view,
IRBs should hesitate to approve such trials, irrespective of
their scientific merit.
Discussion
In this paper, we investigate assumptions that ground
claims about the necessity of placebo-controlled surgical
trials and make suggestions for three measures that may
be of use to IRBs charged with reviewing PCST protocols.
First we argue that there is a need for reliable and valid
evidence about surgical interventions in view of their
extent, irreversibility and cost. We present evidence for
the existence of the surgical placebo effect and argue that
given the placebo response, PCSTs are necessary, in cases
where there is no appropriate surgical comparator, to
provide robust evidence about the efficacy of surgical
interventions that is not otherwise obtainable. In the
second part of the paper, we propose three specific
measures to increase the ethical acceptability of PCSTs.
First, we argue that structured consultation with the rele-
vant patient community might provide valuable informa-
tion to IRBs weighing up the risks and benefits of particular
PCSTs. Second, we advocate the use of educational mate-
rials, informed by patient consultation, to mitigate as far as
possible the therapeutic misconception. Third, we argue
that, given the risks to which they are exposed, formal
agreement should be sought from non-surgeon clinicians
who are necessarily involved in the surgical intervention.
This paper draws on previous qualitative research under-
taken by two of the authors into the design, acceptability
and feasibility of PCSTs [14,17].
Is there a need for placebo-controlled surgical trials?
Placebo-controlled surgical trials entail the risk of harms
to participants, and therefore warrant careful analysis of
their alleged necessity. Here we argue that surgery is an
important and costly health care intervention, and as
such, should be backed by the strongest possible evidence
base, which at times, includes that generated by PCSTs.
Surgery plays an increasing role in modern health care. It
has been estimated that people living in industrialised
countries will have five surgical procedures during their
lifetimes [18]. In Australia in 2011–12, there were nearly
two and a half million hospital discharges following sur-
gical procedures, an increase of 3.6% over the previous
year [19], p. 211. The increase in surgical procedures may
reflect increased longevity leading to greater numbers of
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cancers amenable to surgical intervention, or the increasing
scope of surgery, for example in the treatment of weight
management. Irrespective of the specific causes, rates of
surgical interventions are on the increase [19].
As rates of surgery rise, so do the costs. These may be
viewed in two ways – health care costs to society of
surgical procedures; and costs to patients in terms of
pain and suffering. For patients, surgical procedures
involve significant disruptions to daily life, including
admission to hospital (in 2010–11, Australian patients
spent a total of 1,653,474 days in hospital for procedures
related to musculoskeletal conditions alone [20], p. 256).
Surgery commonly requires some kind of anaesthesia,
which entails risks over and above those of the surgical
intervention; and the chance of complications such as
infection or excessive blood loss. A period of convales-
cence is usually required following surgery, during which
patients may experience pain, have decreased mobility
and generally be unable to live their normal lives. Finally,
surgery is largely irreversible. It may be possible to remove
a surgical prosthesis, but it is not possible to ‘undo’ an
operation: surgery leaves permanent traces on and in
the bodies of patients.
In addition to these real and potential harms to patients,
surgery can be expensive. The 700,000 annual arthro-
scopic partial meniscectomies mentioned above incur
annual direct medical costs of US$4 billion [15]. Health-
care costs are rising around the world. In all OECD
countries (apart from Finland), health expenditure as a
proportion of GDP rose between 2001 and 2011 [21].
In Australia, for example, expenditure rose from AUD
$63,099 million in 2002 to AUD$140,241 million in
2013 [21]. Given that rates of surgical interventions are
increasing, it is fair to consider that at least a proportion
of these rises in healthcare expenditure are driven by
surgery. Rising costs may of course be justified if increases
in expenditure lead to better health outcomes. And clearly
some surgical interventions are highly cost effective. For
example, kidney transplantation is more effective and less
costly than renal dialysis [22]. Nonetheless, in order to
fund the ‘right’ interventions, there is a need for research
capable of discerning between those interventions that are
effective and those that are no better than placebo, as the
latter are potentially both harmful and wasteful [9,12].
This need for evidence of efficacy does not automatic-
ally translate into a need for PCSTs unless there are
reasons to believe that PCSTs are required for developing
a body of evidence sufficient to justify the surgical inter-
vention in question. Placebo surgery may be unwarranted
for two different sorts of reasons. In some cases, the new
intervention can be compared directly with an existing
surgical treatment that is known to be effective and
safe, in which case a randomized controlled trial doesnot need a placebo arm. In other cases placebo surgery is
unwarranted because the patient’s condition requires some
surgical intervention to avert a potentially catastrophic out-
come. For example, it would not be warranted to do a
PCST for ruptured cerebral aneurysms, or appendicitis, as
it would not be ethical to allocate participants to a placebo
given that effective treatments for these conditions exist,
and without some intervention, the patient is at unaccept-
ably high risk of an adverse outcome.
The strength of PCSTs is that they have the potential
to disentangle the causal effects of the surgical intervention
from any potential placebo effects. Here we must clarify
exactly what work the placebo performs in PCSTs, for as
London and Kadane note, there are two meanings for
the term “placebo effect” [5]. The first is methodological,
where placebos are used to help control for as many
variables as possible in a research trial, so that any
effects of the active intervention may be attributed to
that intervention rather than to other causes, such as
the act of being admitted to hospital or anaesthetised.
Here the placebo has an epistemic function – to sort out
causal from other variables [23]. Second, placebos may
have a therapeutic effect. This refers to the phenomenon
of a person experiencing beneficial effects from an
intervention which is provided in a therapeutic guise
but which is deemed by health care providers to lack
specific therapeutic powers, be these pharmacological,
surgical or other [24]. In PCSTs, placebos control for
both the therapeutic placebo effect of the intervention,
and also serve an epistemic role to control for all other
non-specific effects such as the natural course of the
disease or regression to the mean. However, we believe
PCSTs are of value only to the extent that there are
good reasons to believe that there is a placebo effect in
surgery, as if there is not, PCSTs are never justified.b
In addressing this point, we seek to provide a solid
foundation for the work of other authors [8,12,25] who
have proposed criteria that should be met in order to
justify performing specific PCSTsc; our aim is to examine
the assumption about the placebo effect that underlies
their support for PCSTs. We now turn to evidence for
the existence of a surgical placebo effect.
Beecher’s 1961 paper on surgery as placebo is founda-
tional in this regard [26]. Beecher analysed the results of
a number of trials of internal mammary artery ligation
for severe angina. The trials are of varying methodological
quality, but include two randomised placebo-controlled
studies [27,28]. Beecher discusses the remarkable recovery
of one patient in the Cobb et al. trial who, after receiving
the placebo operation, increased his exercise tolerance
from 4 to 10 minutes and reversed the ECG signs of
ischemia that previously occurred within 4 minutes. As
Beecher notes, “It is of such “convincing” objective stuff
that new operations are made” [26], p. 1104. Individual
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evidence of placebo effects following surgical interventions
[2,15,26].
A systematic review of the placebo effect in eight surgi-
cal trials found that between 30-100% of participants in
the placebo groups showed improvements in outcomes
including pain, exercise tolerance, and dizziness, thereby
supporting the claim that surgery appears to be associated
with large placebo effects [29]. PCSTs seemed able to
distinguish between effective and ineffective surgical
interventions, in that of the eight trials included in the
review, six showed no difference between placebo and a
range of surgical interventions, and two showed that
active surgery was more effective than placebo. Like the
results of individual PCSTs, this review provides grounds
for accepting that there is a surgical placebo effect.
Despite this evidence, the existence and importance
of a surgical placebo effect has been disputed [30].
Hróbjartsson and Gøtzsche argue that Beecher and others
calculate the placebo effect as change against baseline for
the group receiving the placebo intervention, but this does
not allow researchers to distinguish between other factors
that might cause an apparent improvement including the
natural course of the disease, or regression to the mean.
They claim, “The reported large effects of placebo could
therefore, at least in part, be artefacts of inadequate
research methods” [31], p. 1594. However, the recent PCST
by Sihvonen et al. [15] includes a separate publication with
a detailed description of the study protocol that explicitly
addresses these kinds of methodological criticisms [32].
Thus while it is possible that poorly designed PCSTs
may not isolate the placebo effect from other causes of
improvements, this criticism is not valid for all PCSTs
demonstrating a placebo effect, and does not undermine
the general claim that there is a surgical placebo effect.
In their review, Hróbjartsson and Gøtzsche make an
important distinction concerning the kinds of outcomes
where placebo effects are observed [31]. They conclude
that there is little evidence that placebos have powerful
clinical effects, where outcomes are binary (i.e. present
or absent), or continuous and objectively assessed, such as
physiological variables measured by health professionals.
In contrast, where outcomes are subjectively assessed, and
especially if continuous rather than binary, they found a
significant placebo effect when compared with no treat-
ment. Notably, pain is the outcome most powerfully
affected by placebo interventions. This point is relevant
for PCSTs as surgery is increasingly being used for elective
and quality of life interventions with subjective outcomes,
thus for interventions in which the placebo effect is likely
to be most evident [9].
Given these findings, which have been consistent over
time, it is reasonable to accept that surgery does exert a
placebo effect, especially where the relevant outcomes aresubjective and continuous, such as relief from symptoms
or impact on quality of life [33]. This creates a prima
facie justification for PCSTs to assess the efficacy of
interventions designed to achieve these outcomes, because
well-designed PCSTs can demonstrate whether or not the
intervention is more effective than the placebo in causing
observed changes in outcomes.
Another line of criticism accepts that while there may be
an in-principle justification for PCSTs, specific instances of
PCSTs are unjustified [30,34]. Polgar and Ng claim that the
trials of both foetal tissue implants for Parkinson’s Disease
[3] and the arthroscopy trial [2] were unjustified as the
information they yielded could have been obtained in
other ways. For example, they write, “It is evident that
arthroscopy was not an effective treatment for osteo-
arthritis because the improvements on key outcome
measures were less than the ‘minimal important’ stan-
dards specified in Moseley et al. (2002). The conclusion
was evident from the outcomes for the two treatment
groups without reference to the results of the placebo
controls” [30], p. 293. However, this criticism seems to
miss the mark as the point that Moseley et al. make from
their trial is that the active treatment was not better than
placebo, therefore any observed effects were likely due to
placebo rather than the active surgery. As with other
critics [31], the points raised by Polgar and Ng are not
sufficient to reject all PCSTs, and can be addressed by
methodological rigour in at least some cases.
One important aspect of methodological rigour con-
cerns the placebo itself, which, to be appropriate, must
maximise the mimic whilst minimising the risk. The aim
is for patients to receive a placebo intervention that is
similar enough to the active intervention to be convincing,
but omits any known therapeutic aspects [13]. In order to
fulfil the epistemic function that is sought in PCSTs, the
placebo intervention must lack what are thought to be the
therapeutic parts of the procedure; the placebo must be
inert, insofar as this is possible. Birch argues that surgical
placebos are never inert, because any surgical wounding
triggers local and systemic physiological responses that
may influence the body’s response to the index condition
and thereby elicit a biologically mediated improvement
[35]. It is not clear what kind of evidence could resolve
this question. Surgical placebos are clearly likely to have
greater biological effects compared with pharmaceutical
placebos such as sugar pills, but even the latter are not
completely inert given that the body is active in the
process of ingestion and digestion of the pill. Nevertheless,
given that PCSTs have convincingly distinguished between
effective and ineffective surgical interventions [26,36], it
seems warranted to assume that they are inert enough to
fulfil their epistemic function in PCSTs.
Surgical placebos also must be convincing enough to
prevent participants from guessing which intervention
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goal: there are examples in the literature of plausible
mimics, in that patients and those assessing outcomes
have been unable to tell whether or not an individual
patient received the therapeutically-intended interven-
tion or the placebo [14,15,17,33].
In this section we argued for the desirability of evidence
about the efficacy of surgical interventions, given their
individual and public costs, and the role of PCSTs in
providing this evidence so long as claims about the
existence of the placebo effect of surgery are warranted.
There is consistent evidence for the existence and import-
ance of a surgical placebo effect, thereby justifying a
requirement for PCSTs for at least some interventions,
especially where these aim to alleviate pain or improve
quality of life. Nonetheless, PCSTs entail balancing the
present exposure of individual participants to risk of
surgical harms against the knowledge gains and likely
benefit to future patients and the wider population. In the
next section we make three suggestions for strengthening
the ethical acceptability of PCSTs by consulting the
relevant patient population about acceptable risks and
benefits; developing educational materials to address the
therapeutic misconception; and taking account of the
roles of non-surgeon clinicians in PCSTs.
Three proposals to strengthen the ethical acceptability
of PCSTs
There are two groups who are rarely included in any
formal way in debates about which PCSTs are ethically
justifiable. The first group is that of the patient population
for whom the intervention may be indicated, and who will
therefore be affected by the outcome of the trial; and
the second are the non-surgeon clinicians involved in
delivering the intervention or placebo. We suggest struc-
tured engagement with both groups in order to strengthen
the ethical acceptability of methodologically justified
PCSTs. Consultation with patients will help to address
concerns about the risk-benefit balance of the trial and
the adequacy of informed consent, while consultations
with non-surgeon clinicians accords appropriate respect
to those who necessarily become involved in the research
as de facto collaborators if a PCST goes ahead, and who
thus may be asked to engage in deception or expose
themselves to professional risks.
Patients’ views can inform ethical deliberation about
PCSTs in important ways [37]. For interventions to treat
chronic conditions, those who are potential recipients of
the proposed intervention are, through personal experi-
ence, generally well-informed about the nature of the
condition and the strengths and weaknesses of current
treatments. The affected group has a particular interest
in understanding what is proposed and how it might
affect them. This patient-held information is relevant forweighing up the risks and benefits of research as this is
the cohort to whom any benefits will accrue (broadly
understood, as the research will benefit future patients
rather than the specific individuals consulted) if the
intervention proves successful, and it is from this group
that participants will be drawn if the research goes
ahead. Patients affected by the index condition have a
thorough understanding of the potential impact should
the experimental intervention prove successful [17]. They
are also the ones who would potentially undergo ineffect-
ive treatment if such a procedure became routine without
rigorous trial. Their knowledge and experience are there-
fore highly relevant in weighing up risks and benefits of
specific PCSTs. If members of the affected patient group
consider that the potential benefits are such that at least
some of them would consider participating in a PCST, this
is relevant information for IRBs to take into account in
their deliberations.d IRBs that prohibit PCSTs remove the
option of research participation from those who stand to
benefit from the results of the research, whether or not
the intervention itself is successful. On the other hand,
IRBs that permit PCSTs without relevant consultation risk
approving potentially harmful research, the outcomes of
which are not viewed as valuable to patients.
In our view, deliberations about the acceptability of
individual PCSTs should be informed by views from the
relevant patient cohort about the risks and benefits of
the research to them. This requires researchers to consult
with patient groups and synthesise and present evidence
about their views as part of their IRB application. Any
consultation should be performed in a structured and
rigorous way using appropriate qualitative methodology.
This process of patient consultation will serve two purposes
as it will address feasibility requirements (for example if the
placebo is unacceptable, recruitment is unlikely to succeed)
as well as inform ethical deliberation. We note that this
may be seen as unduly burdensome – performing “pre-
research” to develop the IRB application. However, there
is increasing advocacy for co-production of research
(research developed with potential participants) [38],
some of which, such as the Peninsula Cerebral Research
Unit in the UK, have active programs for including
patients and their families in the generation of research
questions.e Our suggestion sits well with these developing
standards. In some circumstances it may be desirable for
national or international bodies to perform some of this
preliminary work, ready for uptake by research teams.
Finally, it is possible for funding bodies to release funds
in a staged manner, which will allow for the necessary
evidence to be gathered prior to moving to full funding
of the proposal. There is no doubt that PCSTs are complex
and challenging to implement but we do not believe that
adding a requirement for consultation with patient groups
will render them unmanageable. Furthermore, such pre-
Rogers et al. BMC Medical Ethics 2014, 15:78 Page 6 of 10
http://www.biomedcentral.com/1472-6939/15/78research may save considerable money and time if it averts
full-blown trials of interventions that are unacceptable to
members of the participant group, or likely to fail due to
problems with recruitment.
Pre-research consultation has been used successfully for
other controversial clinical trials. For example, Marsden
and Bradburn report on the role of consultation with
patient groups in assessing the acceptability of a trial of
hormone replacement therapy (HRT) in women with
breast cancer, which entails risks related to the oestrogen-
dependence of most breast cancers [39]. Along similar
lines, Koops and Lindley report on the role of focus
groups with patients in confirming the acceptability of
a trial for a high-risk stroke treatment. In this case, the
pre-research with patients led to changes to patient
information leaflets, and helped in terms of gaining IRB
approval for the trial [14,40].
Our second suggestion for improving the ethical ac-
ceptability of PCSTs is to develop materials to address
the concern that informed consent is an inadequate
protection because participants in PCSTs are vulnerable
to the therapeutic misconception. This is the phenomenon
that, despite explanations about trial design and random-
isation, patients believe that their clinician/researcher will
act in their best interests, and that the trial is a form of
therapy [41]. There is evidence to suggest that participants
do not fully appreciate the processes of clinical research
[42,43]. Studies have shown that patients misunderstand
the nature of research including the randomisation
process, and tend to believe that their doctor will act in
their best interests, notwithstanding their enrolment into
a trial [44,45].
We agree that patients/participants are vulnerable to
the therapeutic misconception and that this is a potential
ethical challenge for PCSTs. However we disagree that the
most appropriate remedy for this vulnerability is for IRBs
to prohibit PCSTs. It may be ethically more appropriate to
foster the capacity of potential participants better to under-
stand the nature of clinical research and the dual role of the
clinician/researcher. At the moment, IRBs have the options
of prohibiting the trial or relying on individual informed
consent to address any misconceptions. Neither of these
options is ideal in terms of addressing the relevant vul-
nerability [46,47]. The prohibition response is protective
but does nothing to foster or support the understanding
or decision-making capacity of the patients/participants.
Additionally, routinely prohibiting PCSTs may leave
patients worse-off. If the trial does not go ahead and
the intervention therefore does not enter clinical practice,
they are left with one less potential option for treatment.
If the intervention is introduced into practice without
proof of efficacy, they are at risk of receiving a treatment
option that may not provide any benefit over placebo, or
may be harmful.The autonomy-respecting option of relying upon in-
formed consent seems to deny any vulnerability on the
part of patients/participants, and is known to be inadequate
in many circumstances: the therapeutic misconception is
certainly not limited to PCSTs [44]. We propose that one
ethically appropriate way to address participant vulnerabil-
ity to misconceptions is to draw upon the expertise of
patient groups in developing educational materials about
the trial. This could be achieved in a two step process: the
first step would be part of the patient cohort consultation
described above. As well as canvassing views about
harms and benefits, the consultation could also identify
issues likely to require clarification. In the second step,
educational materials with information about the trial
could be tested and refined if necessary with focus
groups. The materials would specifically address likely
misconceptions associated with a particular trial with
the relevant patient group, along the lines of patient
decision aids which have been developed to help people
deliberate over and make treatment decisions [48]. Such
materials could be designed for use in a public way via
patient networks, well before trial enrolment commences,
as well as during the informed consent process. The aim
of these materials would be to increase research literacy,
specifically address therapeutic misconceptions about
the research trial for the particular intervention under
investigation, and foster the decision making capacities
of patients. This response provides a more nuanced and
ethically justifiable way of addressing potential vulner-
ability rather than a blanket prohibition by IRBs [46].
This approach is supported by existing empirical work
which suggests that patients are able to consider the risks
and benefits of PCSTs, decide whether or not participation
would be personally acceptable, and develop views about
whether or not IRBs should approve the trials. Frank
et al. surveyed three patient cohorts about the ethical
acceptability of two hypothetical trials (one open, one
blinded using placebo surgery) of a gene transfer agent
for Parkinson’s Disease (PD). The three cohorts were
patients with PD, patients with neurological conditions
other than PD, and patients attending a community-based
general internal medicine practice. Overall, patients with
PD were less willing to participate in either trial than those
without PD, but despite this, 41% indicated willingness to
participate in the open trial and 24% to participate in the
blinded study. When asked to take the perspective of an
IRB, the three cohorts consistently favoured approving the
open trial (83%) and, to a lesser extent, the blinded trial
(54%). Study participants cited reasons for approving the
hypothetical PCST consistent with those in the literature,
such as methodological need, adequate informed consent,
acceptable risk benefit ratio, and societal benefit outweigh-
ing the risks. Similarly, those who thought that an IRB
should prohibit the PCST gave reasons including risk, lack
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controlled trials are prima facie unethical [49].
These findings are consistent with Campbell et al. who
asked patients with osteoarthritis about the acceptability
of a PCST of knee arthroscopy [14,17]. They found that
many participants identified and supported the notion of
a PCST (and some went on to consent to a formal pilot
of a PCST), while others were sceptical of the need for a
placebo. In discussing their own potential involvement in
the trial, participants expressed a variety of views includ-
ing a desire to help others and the hope that they would
be allocated to the active rather than placebo arm of the
trial. Others seemed to discount the possibility of harm
from the placebo, or noted the potential inconvenience of
being in a trial.
Thus research with relevant patient cohorts indicates
that patient groups can be a rich source of information
relevant to the development of PCSTs. The findings
indicate qualified support for PCSTs and flag areas of
misunderstanding about trial participation that should
be addressed in the pre-consent educational materials that
we advocate. There is no indication that the misconcep-
tions of potential participants in PCSTs are greater than or
differ from misconceptions experienced by participants in
other types of clinical research. Importantly, the research
we have reviewed does not support the view that patients
are unable to deliberate about PCSTs. We therefore
recommend the development of educational and decision-
support materials should a PCST go ahead.
Our third suggestion concerns staff included in PCSTs
such as anaesthetic, theatre and recovery staff, and those
involved in any post-operative care (hereafter referred to
as non-surgeon clinicians). Accounts of research ethics
rightly focus on respecting and protecting participants,
where respect is demonstrated through the process of
informed consent [50]. One of the ethical justifications
for informed consent is that it provides a mechanism for
treating the participant as an end in him or herself,
rather than treating him/her instrumentally, merely as a
means to the researchers’ ends. Through the consent
process, potential participants have the opportunity to
accept or decline involvement in the research, and if they
freely consent, concern about treating them instrumen-
tally is alleviated. Other parties involved in the research,
such as the clinicians who recruit patients or administer
interventions, are not formally asked for their consent in
the same way because they are not deemed to be vulner-
able in the way that participants may be. They are usually
the peers of the researcher and generally free to sign up to
the protocol or to decline involvement with no adverse
consequences. However, this approach is problematic in
complex research interventions like surgery. Individual
surgeons have the right to agree or decline participation in
a PCST, but if they elect to participate, the nature ofsurgery means that their agreement necessarily commits
non-surgeon clinicians to participation as de facto collabo-
rators, because the surgery cannot proceed without
them. If there is no explicit or formal process for seek-
ing their agreement, then the surgeon’s commitment to
be part of a PCST could appear to treat non-surgeon
clinicians instrumentally as it does not accord them the
respect of deciding for themselves whether or not to
participate in the research.
This is especially problematic for ethically contentious
research such as PCSTs. Participation in a PCST may
expose non-surgeon clinicians to being deemed respon-
sible for any harms that might occur during the trial,
irrespective of whether or not they explicitly agreed to
participate (e.g. an anaesthetic mishap during a placebo
procedure). In the surgical setting, it is unclear as to what
power non-surgeon clinicians have to refuse participation,
and this may differ between institutions. Research with
anaesthetists shows a range of views about a proposed
PCST of knee arthroscopy [14]. As consultants and peers
to surgeons, anaesthetists may well have the power to re-
fuse to participate. However other non-surgeon clinicians,
especially nursing staff, may find themselves committed
by their surgeon (or anaesthetist) to a PCST about which
they hold ethical reservations.
There are a number of issues here. First, participating
in research is a legitimate part of the professional role of
clinicians in publicly funded hospitals, so it might be
considered unnecessary to seek agreement from all clini-
cians for all research. We agree that it is not unreasonable
to expect research participation from clinicians; however,
surgical research raises ethical questions in this regard. As
we have noted above, non-surgeon clinicians lack the
same power as surgeons in terms of participation in the
research, as a surgeon’s commitment to a trial is under-
stood to include the necessary surgical team to perform
the research. Furthermore, this is not just a problem for
individuals. While individual non-surgical clinicians may
refuse, someone in the relevant role has to agree as there
is a strong expectation that the research will go ahead with
the requisite staff. This may be especially problematic if
members of particular groups of non-surgeon clinicians
tend to disagree about the importance and legitimacy of
either the research question or the methodology of the
proposed PCST. Next, the rewards of research may be un-
equally distributed. While chief investigators may receive
recognition and advancement for their research activities
and enjoy the creative aspects of research, these rewards
may not be available to non-surgeon clinicians in the con-
text of PCSTs where they are drawn in to other’s research
activities. In addition, the ethically contested nature of
PCSTs, the need for non-surgeon clinicians to engage in
potentially deceptive behaviour in order to maintain the
blinding, and the risk of being held responsible for patient
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thinking that PCSTs are a special case which does warrant
an explicit process for seeking agreement from staff who
are necessarily involved just because it is a surgical trial.
Second, it may be that governance approvals are, or
should be, the mechanism for dealing with these concerns.
These typically occur after IRB approval, and are a site-
specific examination of the governance and resource
implications of the proposed research. It may be that
this process will allow non-surgeon clinicians to voice
their concerns, but if the concerns are primarily ethical
rather than governance, they may be discounted on the
grounds that the research already has ethics approval.
Governance approvals do not ensure respect for the
views and autonomy of participants in the way intended
by formal consent processes mandated by IRBs.
Third, it may be impractical to seek explicit consent
from every non-surgeon clinician affected by a PCST. It is
already costly and difficult to mount surgical trials, such
that adding a layer of consent maybe too burdensome and
lead to less surgical research. This is a serious concern, yet
research indicates that it is feasible to consult with those
likely to be affected by a PCST [14]. Formalising this
process would allow explicit consideration of the ethical
concerns of non-surgeon clinicians.
In our view, non-surgeon clinicians who are necessarily
involved in PCSTs should be recognised as relevantly
vulnerable and their individual agreement should be sought
prior to their inclusion in the research. This will require
developing mechanisms for seeking agreement from non-
surgeon clinicians to participate in PCSTs. Such agreement
should be separate from governance approvals or feasibility
assessments. Non-surgeon clinicians should be adequately
informed about the proposed trial and then decide for
themselves whether or not they are willing to participate. In
addition, insurance arrangements for the trial should in-
clude cover for patient harms arising from placebo proce-
dures in which non-surgical staff are implicated.
Our proposed expansions to the ethical review process
for PCSTs are consistent with but extend beyond the prin-
ciples promulgated by the American Medical Association
regarding PCSTs [51]. The AMA principles engage with
scientific validity and the conditions under which PCSTs
may be justified, and the need for particular attention to
informed consent, as do the works of other theorists [25].
The AMA principles stop short of mandating consultation
with patient groups and the development of educational
materials, and do not include non-surgeon clinicians as
potentially vulnerable and therefore warranting the pro-
tection of formal agreement processes.
Summary
Determining the ethical permissibility of PCSTs is com-
plex. Here we have sought to establish that, given thenature and extent of surgical interventions and the exist-
ence of a surgical placebo effect, there is an in-principle
justification for PCSTs to demonstrate efficacy, especially
where risks of harm have been minimized, the outcomes
are subjective, and there is no surgical comparator. In
such situations, ethical consideration, rather than a blan-
ket prohibition, is warranted. Ethical decision making
about specific PCSTs can be supported by including the
views of patient groups in deliberations about the risks
and benefits of specific trials; developing educational
materials to assist patient decision making; and including
non-surgeon clinicians amongst those who should give for-
mal agreement for participating in PCSTs. These measures
will help to avoid unwarranted prohibitions of PCSTs on
the part of IRBs, strengthen the decision-making of patient
participants, and ensure that non-surgeon clinicians are
not treated instrumentally. And while we have focused
on PCSTs, a similar model may be applicable to other
relevantly similar high risk research.
Endnotes
aPlacebo effects are improvements in a patient’s condition
following an intervention that lacks known therapeutic
mechanisms other than the patient’s belief in its value
(Shapiro AK: Factors contributing to the placebo effect.
Their implications for psychotherapy. Am J Psychother
1964, 18:73–88) [24].
bSome commentators argue that placebo controlled tri-
als may be justified even when there is an active control
available and no therapeutic effect is likely to follow from
the placebo. Temple and Ellenberg, for example, note that
because placebos control for non-specific effects such as
the natural course of the disease or regression to the
mean, they provide information that is not available in a
trial with an active control. They argue that placebo
controls are thus sometimes ethical even when an active
control is available, but only in situations in which the
patient will not be harmed by the delay incurred by treat-
ing with placebo. However, in the context of PCSTs, a
therapeutic placebo effect may be expected, therefore
placebos cannot fulfil the function they identify. (Temple
R, and Ellenberg, S: Placebo-Controlled Trials and
Active-Control Trials in the Evaluation of New
Treatments. Part 1: Ethical and Scientific Issues.
Ann Int Med 2000, 133(6):455–463).
cSee for example, those summarized by Freeman et al.
which include: the importance of the research question;
lack of alternative methods that will provide equivalent
data; methodological rigor including plausible mimic;
indicative but not conclusive evidence that the interven-
tion is effective; and an intervention that is sufficiently
well developed to remain stable and current over the life
of the trial (Freeman TB, Vawter DE, Leaverton PE,
Godbold JH, Hauser RA, Goetz CG, Olanow CW: Use
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based therapy for Parkinson’s disease. N Engl J Med
1999, 341(13):988–992, p.989) [3].
dIt is worth noting that there are risks in both arms of
the trial, placebo and active. There are no guarantees
that the intervention will be effective or that the placebo
will be more harmful than the intervention. For example,
Miller notes that in a placebo-controlled trial of a laser
myocardial revascularization device, there were no differ-
ences in outcomes between active treatment and placebo,
but there were more adverse events in the interven-
tion group (Miller FG: The enduring legacy of sham-
controlled trials of internal mammary artery ligation.
Prog Cardiovasc Dis 2012, 55:246–250) [36].
eSee the information for families about getting involved
at the Peninsula Cerebra Research Unit [http://www.pen-
cru.org/].
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